Employers' costs for specialty drugs are expected to double in the next two to three years and could amount to as much as 40% of an employer's drug spend.
This session focuses on pricing, utilization and benefit plan design strategies for controlling the high cost of these drugs.
- Gregory I. Madsen, Co-CEO, Innovative Rx Strategies, LLC
- Michael J. Staab, J.D., Co-CEO, Innovative Rx Strategies, LLC
Continue by clicking on the following link: